Benzbromarone Tablets

This product is a benzofuran derivative and a uricosuric drug. Its mechanism of action is mainly to inhibit the reabsorption of uric acid by the renal tubules, thereby reducing the concentration of uric acid in the blood. Toxicological studies: According to reports, rats have been reported to have developed liver cancer after long-term oral administration [50 mg/kg/day (about 17 times the clinical dose) for 104 weeks]. In vitro studies have shown that this product also has the effect of promoting peroxisome proliferation in isolated rat liver cells, but has no such effect on human stem cells. Therefore, some literature believes that the effect of this product inducing rat liver cancer may not be extended to humans. There are also documents that believe that this product is safe for patients with kidney and liver diseases based on 10 years of treatment experience, and is suitable for long-term use in patients with kidney and liver diseases or insufficient function.

The main component of this product is benzbromarone. Chemical name: 3,5-dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl-ketone Molecular weight: C17H12Br2O3

This product is white or off-white tablets.

Primary hyperuricemia, intermittent period of gouty arthritis and gouty nodules, etc.

Adults take 50 mg (1 tablet) orally once a day after breakfast. Check serum uric acid concentration 1 to 3 weeks after medication. In subsequent treatment, adults and young people over 14 years old take 50 to 100 mg (1 to 2 tablets) daily, or as directed by a doctor.

Sometimes gastrointestinal discomfort may occur, such as nausea, vomiting, a feeling of fullness in the stomach, and diarrhea. Urticaria (urticaria) rarely occurs. In some cases, conjunctival inflammation (conjunctival moxibustion), short-term impotence, perverted local skin eczema (rash), headaches, and increased urinary frequency may also occur. In some cases, it is also necessary to observe whether liver disease (cytolytic hepatitis) has worsened. Some of these diseases are acute and difficult to control. It has been reported that taking benzbromarone may cause itching, facial redness, erythema, photosensitivity, edema, discomfort in the heart, and other adverse reactions. If adverse reactions not mentioned in the instructions for this product occur, please inform your doctor or pharmacist immediately.

1. Those who are allergic to any ingredient in this product. 2. Those with moderate to severe renal impairment (glomerular filtration rate less than 20ml/min) and patients with kidney stones. 3. Pregnant women, women who may become pregnant, and breastfeeding women are prohibited from using this product.

Precautions for children: The safety and effectiveness of this product for children have not been studied, so it is not recommended for children. Precautions for pregnancy and lactation: 1. Since there is no clinical experience in humans and there are deviations in animal experimental results, it is contraindicated for pregnant patients. 2. It is not clear whether benzbromarone enters breast milk, so it is contraindicated for lactating patients. Precautions for the elderly: The physiological functions of the elderly generally decline, so the dosage should be reduced or follow the doctor's advice.

The uricosuric effect of benzbromarone may be attenuated by salicylates and sulfinpyrazone.

Keep away from light and store in sealed container.

50 mg

60 months.